Loading…
Employees: 125
Size DBV Technologies (DBV.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $633M, the 162nd largest of 206 France companies the cockpit tracks. Shares closed at €1.79 on 6 Nov 2026.
Performance Over six months the shares fell 47.0%, against -19.0% for the median peer and -0.4% for the France market (cap-weighted) — 2nd lowest of 21 in its peer set.
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 | €0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -€15.3M | -€15.6M | -€6.31M | €4.16M | -€20.3M |
| EBITDA | -€167M | -€120M | -€105M | -€89.4M | -€76.3M |
| Net income | -€179M | -€130M | -€105M | -€67.3M | -€91.6M |
| Free cash flow | -€165M | -€108M | -€98.7M | -€74.3M | -€53.7M |
| Capital expenditure | €2.92M | €476,706 | €2.16M | €626,205 | €717,430 |
| Total debt | €19.5M | €18.5M | €14.6M | €13.0M | €9.39M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DBV.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | -6.6% | 3rd highest of 21 |
| 6-month return | -47.0% | -19.0% | 2nd lowest of 21 |
| Distance from 52-week high | -60.1% | -35.8% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 1.0× | -4.9% | +6.5% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | 107.7× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | 2.5× | 12.1% | -5.9% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 2.9× | 23.2% | +21.9% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.4× | 1.1% | -1.6% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 5.1× | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | 2.2× | 0.3% | -17.9% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | 2.6× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | 19.0× | n/a | n/a |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | 2.5× | 25.9% | +10.3% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |